Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

NCT05814939 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-07-29

No results posted yet for this study

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

Conditions

  • Active Ankylosing Spondylitis

Interventions

DRUG

VC005 tablets

VC005 groups repeat administration for 12 weeks

DRUG

Tofacitinib Citrate Tablets

Tofacitinib Citrate groups repeat administration for 12 weeks

DRUG

VC005 Tablets Placebo

VC005 placebo groups repeat administration for 12 weeks

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • Zhanguo Li · Peking University People's Hospital

  • Xu Liu · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-26
Primary Completion
2024-05-11
Completion
2024-05-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05814939 on ClinicalTrials.gov